Updates

DOSE OF REALITY: EXPERT ASSESSMENT CONFIRMS BIG PHARMA’S PRICING OF NEW ALZHEIMER’S TREATMENT EXCEEDS FAIR PRICE

Apr 18, 2023

ICER Analysis of Leqembi Finds $26,500 Price Tag Exceeds Drug’s “Cost Read More

ICYMI: LAWMAKERS MAKE BIPARTISAN CALL FOR FURTHER ACTION TO CRACK DOWN ON BIG PHARMA’S PATENT THICKETS

Mar 28, 2023

Members of Congress Send Letter Encouraging USPTO to Close Loopholes Exploited Read More

CSRXP APPLAUDS REINTRODUCTION OF FAIR DRUG PRICING ACT

Mar 24, 2023

Bipartisan Transparency Legislation Will Help Hold Big Pharma Accountable for Read More

THEY SAID IT! LAWMAKERS SLAM MODERNA FOR EGREGIOUS COVID-19 VACCINE PRICE HIKE

Mar 23, 2023

Senate HELP Committee Members Slam Moderna’s CEO for Instituting Nearly 500 Read More

CSRXP: LAWMAKERS MUST HOLD BIG PHARMA ACCOUNTABLE FOR UNCONSCIONABLE PRICE HIKES ON COVID-19 VACCINES AND TREATMENTS

Mar 22, 2023

Senate HELP Committee Hearing with Moderna CEO Offers Prime Opportunity to Read More

DOSE OF REALITY: LAWMAKERS GET CHANCE TO HOLD BIG PHARMA ACCOUNTABLE FOR COVID-19 PRICE-GOUGING AHEAD OF COMMERCIAL DISTRIBUTION

Mar 20, 2023

Senate HELP Committee to Question Moderna CEO on Nearly 500 Percent Price Hike Read More

BIRDS OF A FEATHER: PFIZER AND SANOFI ACQUIRE FELLOW PRICE-GOUGERS IN LATEST BIG PHARMA M&A DEALS

Mar 17, 2023

Big Pharma Giants With Affinity for Price Hikes Acquire Smaller Brand Name Read More

BIG PHARMA WATCH: NEW REPORT HIGHLIGHTS BIG PHARMA’S RAPIDLY RISING LAUNCH PRICES

Mar 10, 2023

Wall Street Journal Analysis Finds Median Monthly Price for Newly Approved Read More

CSRXP STATEMENT ON ELI LILLY ANNOUNCEMENT ON PRICE OF INSULIN PRODUCTS

Mar 1, 2023

More Big Pharma Companies Should Also Lower Their Insulin Prices Read More

BIG PHARMA WATCH: NYT REPORT DOCUMENTS NARCOLEPSY DRUG MAKER’S EGREGIOUS EXPLOITATION OF PATENT SYSTEM

Feb 28, 2023

Anti-Competitive Strategy Around Brand Name Narcolepsy Medications Blocked Read More

BIG PHARMA EARNINGS WATCH: ABBVIE AND ASTRAZENECA

Feb 28, 2023

Big Pharma Giants Once Again Top Wall Street Expectations in Final Round of Read More